Overall, these findings suggest that X224 and X225 may introduce modest transcriptional and genomic changes; however, these alterations do not appear to translate into clinically significant increases in recurrence, progression, or death compared to tumours with wild-type TP53. The gene discussed is TP53; the disease is neoplasm.